⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8632982 | 0.73 | — | — | |
| SCHEMBL17319722 | 0.73 | — | — | |
| SCHEMBL9346 | 0.69 | — | — | |
| SCHEMBL3678006 | 0.63 | — | — | |
| SCHEMBL24013 | 0.63 | — | — | |
| SCHEMBL25407819 | 0.63 | — | — | |
| SCHEMBL17688348 | 0.63 | — | — | |
| SCHEMBL21351608 | 0.63 | — | — | |
| SCHEMBL17688345 | 0.63 | — | — | |
| SCHEMBL80405 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 318 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423451-B1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | PROPELLON THERAPEUTICS INC (CA) | 2022-08-17 | — | — | EP | claimed |
| CN-109195965-B | Inhibitors of WDR5 protein-protein binding | 普罗佩纶治疗公司 | 2022-07-26 | — | — | CN | claimed |
| CN-110573518-A | Substituted bicyclic pyrimidinyl compounds, compositions and uses thereof | 尤拉·S·赞特里佐斯 | 2019-12-13 | — | — | CN | claimed |
| EP-3423437-A1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | Propellon Therapeutics Inc. (CA) | 2019-01-09 | — | — | EP | claimed |
| EP-3423451-A1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | Propellon Therapeutics Inc. (CA) | 2019-01-09 | — | — | EP | claimed |
| WO-2018137036-A1 | SUBSTITUTED BICYCLIC PYRIMIDINE-BASED COMPOUNDS AND COMPOSITIONS AND USES THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY (CA) | 2018-08-02 | — | — | WO | claimed |
| US-9796708-B2 | Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors | ABBVIE INC. (US) | 2017-10-24 | — | — | US | claimed |
| US-20160060257-A1 | PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2016-03-03 | — | — | US | claimed |
| EP-2970278-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014139328-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-18 | — | — | WO | claimed |
| US-20080004288-A1 | Indazole Sulphonamide Derivatives | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | claimed |
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | claimed |
| US-12030858-B2 | PARP inhibitors for treating cancer and asthma | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2024-07-09 | — | — | US | disclosed |
| EP-3843726-B1 | PARP INHIBITORS FOR TREATING CANCER AND ASTHMA | UNIV OREGON HEALTH & SCIENCE (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3897630-B1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | CELGENE CORP (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-117222625-A | Substituted pyridazinones, salts or N-oxides thereof and their use as herbicidal agents | 拜耳公司 | 2023-12-12 | — | — | CN | disclosed |
| WO-2003051276-A2 | THERAPEUTIC HETEROCYCLES | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051275-A2 | BENZODIAZEPINE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
| EP-0852584-A1 | PEPTIDE DERIVATIVES HAVING ENDOTHELIN RECEPTOR ANTAGONISTIC ACTIVITY | Takeda Chemical Industries, Ltd. (JP) | 1998-07-15 | — | — | EP | disclosed |
| WO-1997011961-A1 | PEPTIDE DERIVATIVES HAVING ENDOTHELIN RECEPTOR ANTAGONISTIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-04-03 | — | — | WO | disclosed |